IGC Pharma (IGC) Income from Non-Controlling Interests (2010 - 2018)
IGC Pharma (IGC) reported Income from Non-Controlling Interests of $634.0 for Q1 2018, up 105.09% year-over-year from $309.13 in Q1 2017, and up 375.65% quarter-over-quarter from -$230.0 in Q4 2017.
IGC Pharma (IGC) Income from Non-Controlling Interests (2010 - 2018) Analysis & Trends
IGC Pharma (IGC) has 9 years of Income from Non-Controlling Interests data on file, last reported at $634.0 in Q1 2018.
- Income from Non-Controlling Interests for Q1 2018 came in at $634.0, up 105.09% year-over-year; the trailing twelve-month figure through Jun 2018 was $320.0 (down 98.42% YoY), and the FY2017 annual result was $14399.0, up 156.02% from the prior year.
- Income from Non-Controlling Interests grew to $634.0 in Q1 2018 per IGC's latest filing, from -$230.0 in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $38088.0 in Q4 2016 and troughed at -$42000.0 in Q4 2015.
- A 5-year average of -$3364.4 and a median of -$5073.0 in 2016 frame the typical range for Income from Non-Controlling Interests.
- The sharpest annual moves came in 2014 and 2015: Income from Non-Controlling Interests sank 15820.44% in 2014, then jumped 450.89% in 2015.
- A 5-year view of Income from Non-Controlling Interests shows it stood at -$8882.0 in 2014, then sank by 372.87% to -$42000.0 in 2015, then jumped by 190.69% to $38088.0 in 2016, then sank by 100.6% to -$230.0 in 2017, then soared by 375.65% to $634.0 in 2018.
- Business Quant data shows IGC's Income from Non-Controlling Interests at $634.0 in Q1 2018, -$230.0 in Q4 2017, and -$84.0 in Q3 2017.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -13.75 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | - |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2018 | 634.00 |
| Dec 31, 2017 | -230.00 |
| Sep 30, 2017 | -84.00 |
| Jun 30, 2017 | -319.00 |
| Mar 31, 2017 | -12,449.00 |
| Dec 31, 2016 | 38,088.00 |
| Sep 30, 2016 | -5,073.00 |
| Jun 30, 2016 | 23,238.00 |
| Mar 31, 2016 | 28,298.00 |
| Dec 31, 2015 | -42,000.00 |
| Sep 30, 2015 | -16,979.00 |
| Jun 30, 2015 | 29,085.00 |
| Mar 31, 2015 | -40,118.00 |
| Dec 31, 2014 | -8,882.00 |
| Sep 30, 2014 | -28,454.00 |
| Jun 30, 2014 | -8,289.00 |
| Mar 31, 2014 | -13,660.00 |
| Dec 31, 2013 | -5,336.00 |
| Sep 30, 2013 | 181.00 |
| Jun 30, 2013 | -1,173.00 |